Apollo Health Ventures

Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

Developer of therapeutic medicines intended to treat age-related diseases and improve healthy longevity. The company researches FOXO proteins that regulate multiple genes involved in processes like stress resistance, and metabolism and develops novel modulators of a central stress response pathway to modulate aging through genetics, enabling patients to extend the years of healthy living.

Booster Therapeutics is a biotechnology company focused on developing innovative medicines aimed at addressing diseases associated with aging. The company specializes in regulating cellular homeostasis, a process essential for maintaining balance within cells. By targeting the cellular systems responsible for this regulation, Booster Therapeutics aims to eliminate toxic accumulations that can lead to various aging-related conditions. Through its research and development efforts, the company seeks to provide effective treatments that can prevent and manage these diseases, enhancing overall health and longevity.

Aeovian Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for age-related and rare diseases. Founded in 2012 and based in the San Francisco Bay Area, the company specializes in compounds that inhibit the mTORC1 and mTORC2 pathways. These therapeutics aim to address the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these fundamental factors, Aeovian Pharmaceuticals seeks to provide effective treatment options for patients and healthcare professionals.

Cleara Biotech B.V., based in Utrecht, the Netherlands, focuses on developing therapeutics aimed at selectively eliminating senescent and senescent-like cancer cells. The company is particularly engaged in creating FOXO4-based anti-senescence drugs designed to counteract chemotoxicity and address therapy-resistant cancer cells. By targeting these problematic cells, Cleara Biotech seeks to advance cancer treatment and improve patient outcomes.

Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

Bloom Science, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing neuroprotective medicines that leverage the microbiome to address epilepsy and other neurological conditions. Established in 2017, the company employs its proprietary IrisRx™ discovery platform, which utilizes insights into the Gut-Brain Axis to create therapeutics targeting rare and complex neurological disorders. This innovative approach aims to translate the therapeutic benefits of the ketogenic diet into effective medications, enhancing safety and efficacy. Bloom Science is advancing a diverse pipeline of therapeutic candidates aimed at conditions such as Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and various neurodegenerative and cognitive disorders, with a commitment to providing improved treatment options for patients facing serious, life-altering illnesses.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

Samsara Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapies for age-related diseases and unmet medical needs. Founded in 2018 and headquartered in Hamburg, Germany, with additional operations in Oxford, Paris, Graz, and San Diego, the company utilizes a unique screening platform centered on geroprotectors to create caloric restriction mimetics (CRM) that target the core mechanisms of aging, such as proteostasis, autophagy, and energy metabolism. Samsara's research and development activities include the identification, chemical optimization, and in vivo validation of compounds that aim to extend healthy lifespan and address rare genetic and neurodegenerative disorders.

Aeovian Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for age-related and rare diseases. Founded in 2012 and based in the San Francisco Bay Area, the company specializes in compounds that inhibit the mTORC1 and mTORC2 pathways. These therapeutics aim to address the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these fundamental factors, Aeovian Pharmaceuticals seeks to provide effective treatment options for patients and healthcare professionals.

Samsara Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapies for age-related diseases and unmet medical needs. Founded in 2018 and headquartered in Hamburg, Germany, with additional operations in Oxford, Paris, Graz, and San Diego, the company utilizes a unique screening platform centered on geroprotectors to create caloric restriction mimetics (CRM) that target the core mechanisms of aging, such as proteostasis, autophagy, and energy metabolism. Samsara's research and development activities include the identification, chemical optimization, and in vivo validation of compounds that aim to extend healthy lifespan and address rare genetic and neurodegenerative disorders.

Cleara Biotech B.V., based in Utrecht, the Netherlands, focuses on developing therapeutics aimed at selectively eliminating senescent and senescent-like cancer cells. The company is particularly engaged in creating FOXO4-based anti-senescence drugs designed to counteract chemotoxicity and address therapy-resistant cancer cells. By targeting these problematic cells, Cleara Biotech seeks to advance cancer treatment and improve patient outcomes.

Aeovian Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for age-related and rare diseases. Founded in 2012 and based in the San Francisco Bay Area, the company specializes in compounds that inhibit the mTORC1 and mTORC2 pathways. These therapeutics aim to address the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these fundamental factors, Aeovian Pharmaceuticals seeks to provide effective treatment options for patients and healthcare professionals.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.